Albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
A chromatography column is a device used in chromatography for the separation of chemical compounds. A chromatography column contains the stationary phase, allowing the mobile phase to pass through it.
Migraine is common, with around 33% of women and 18% of men affected at some point in their lifetime. According to the Global Burden of Disease Study 2021, approximately 14% (1.16 billion) of people worldwide are affected by migraine in a given year. In the United States, about 6% of men and 18% of women experience a migraine attack in a given year, with a lifetime risk of about 18% and 43%, respectively. In Europe, migraine affects 12–28% of people at some point in their lives, with about 6–15% of adult men and 14–35% of adult women getting at least one attack yearly. Rates of migraine are slightly lower in Asia and Africa than in Western countries. Chronic migraine occurs in approximately 1.4–2.2% of the population; and affects around 8% of individuals with migraines. Onset can be at any age, but prevalence rises sharply around puberty, and remains high until declining after age 50. Before puberty, boys and girls are equally impacted, with around 5% of children experiencing migraine attacks. From puberty onwards, women experience migraine attacks at greater rates than men. From age 30 to 50, up to 4 times as many women experience migraine attacks as men; this is most pronounced in migraine without aura.
== Signs and symptoms == The first skin changes in calciphylaxis lesions are mottling of the skin and induration in a livedo reticularis pattern. As tissue thrombosis and infarction occurs, a black, leathery eschar in an ulcer with adherent black slough develops. Surrounding the ulcers is usually a plate-like area of indurated skin. These lesions are always extremely painful and most often occur on the lower extremities, abdomen, buttocks, and penis. Lesions are also commonly multiple and bilateral. Because the tissue has infarcted, wound healing seldom occurs, and ulcers are more likely to become secondarily infected. Many cases of calciphylaxis lead to systemic bacterial infection and death. Calciphylaxis is characterized by the following histologic findings:
== Areas of application == This technique can be utilized in the aviation industry. As in principle, prepreg has the potential to be processed batch sizes. Despite fiber glass having high applicability in aircraft specifically small aircraft motors, carbon fiber is employed in this type of industry at a higher rate, and the demand for it is increasing. For example, the characterization of Airbus A380 is handled by means of a mass fraction. This mass fraction is about 20%, and the Airbus A350XWB by a mass fraction of about 50% of carbon fiber prepregs. Carbon fiber prepregs have been used in the airfoils of the Airbus fleet for more than 20 years. The usage of prepreg in automotive industry is used at relatively limited quantities in comparison with other techniques like automated tape lay-up and automated fiber placement. The main reason behind this is the relative high cost of prepreg fibers as well as the compounds used in molds. Example of such materials are bulk moulding compound (BMC) or sheet moulding compound (SMC). This material is used to make the cockpit doors on the Airbus A320. This material provides bulletproofness.
Sources: en.wikipedia.org
A spider positioned in the middle of the web makes for a highly visible prey for birds and other predators, even without web decorations; many day-hunting orb-web spinners reduce this risk by hiding at the edge of the web with one foot on a signal line from the hub or by appearing to be inedible or unappetizing. Spiders do not usually adhere to their own webs, because they are able to spin both sticky and non-sticky types of silk, and are careful to travel across only non-sticky portions of the web. However, they are not immune to their own glue. Some of the strands of the web are sticky, and others are not. For example, if a spider has chosen to wait along the outer edges of its web, it may spin a non-sticky prey or signal line to the web hub to monitor web movement. However, in the course of spinning sticky strands, spiders have to touch these sticky strands. They do this without sticking by using careful movements, dense hairs and nonstick coatings on their feet to prevent adhesion.
== Biosynthesis == 1-Methylnicotinamide can be produced in the liver by nicotinamide N-methyltransferase (NNMT). The reaction takes place during the metabolism of NAD+ (nicotinamide adenine dinucleotide). NNMT is also present in brain tissue, adipose tissue, muscle tissue, kidneys, and skin. NNMT (nicotinamide N-methyltransferase) is an enzyme that in humans is encoded by the NNMT gene. NNMT catalyzes the methylation of nicotinamide and similar compounds using the methyl donor S-adenosyl methionine (SAM-e) to produce S-adenosyl-L-homocysteine (SAH) and 1-methylnicotinamide. NNMT is highly expressed in the human liver.
==== Deluge of wars ==== During the reign of John II Casimir Vasa (r. 1648–1668), the third and last king of his dynasty, the nobles' democracy fell into decline as a result of foreign invasions and domestic disorder. These calamities multiplied rather suddenly and marked the end of the Polish Golden Age. Their effect was to render the once powerful Commonwealth increasingly vulnerable to foreign intervention.
Offensive realists accept that threatened states usually balance against dangerous foes, however, they maintain that balancing is often inefficient and that this inefficiency provides opportunities for a clever aggressor to take advantage of its adversaries. Buck passing, rather than joining a balancing coalition, is another tactic offensive realists point to when disputing the balance of power theory. Offensive realists believe that internal balancing measures such as increasing defense spending, implementing conscription, are only effective to a certain extent as there are usually significant limits on how many additional resources a threatened state can muster against an aggressor. However, since offensive realists theorize that states are always seeking to maximize their power, states are "effectively engaged in internal balancing all the time".
=== No development reported === AB-1224 – microbiome modulator AGX-201 (histamine dihydrochloride salt) – histamine H1 receptor antagonist and histamine H3 receptor agonist Aminolevulinic acid/sodium ferrous citrate (5-ALA-SFC, 5-ALA/SFX; sodium ferrous citrate/aminolevulinic acid; SPP-003) – erythropoiesis stimulant and photosensitizer Aripiprazole transdermal (AQS-1301; transdermal aripiprazole) – dopamine D2 and D3 receptor partial agonist, serotonin 5-HT1A and 5-HT7 receptor partial agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist or inverse agonist, and atypical antipsychotic BAER-101 (AZ-7325; AZD-7325) – selective GABAA α2 and α3 subunit-containing receptor positive allosteric modulator BBP-472 – phosphatidylinositol 3 kinase β (PI3Kβ) inhibitor Fasoracetam co-crystallised (co-crystallised fasoracetam; AEVI-004) – various actions and racetam Guanfacine once-daily (Guanfacine Carrier Wave; SPD-547) – α2-adrenergic receptor agonist KBLP-010 – bacteria replacement and microbiome modulator Oxytocin intranasal (OPN-300; OptiNose oxytocin) – oxytocin receptor agonist Research programme: allosteric modulators - Addex Therapeutics (various) – various actions Research programme: antisense oligonucleotide therapeutics - RogCon U.R (RCUR-313, RCUR-SMP) – voltage-gated sodium channel Nav1.2 expression stimulants Research programme: autism and obesity therapeutics - Berand Neuropharmacology – histone deacetylase inhibitors Research programme: brain development disorder therapeutics - Seaside Therapeutics (STX-110) – metabotropic glutamate mGlu5 receptor antagonists and muscarinic acetylcholine M1 receptor antagonists Research programme: cannabinoid receptor modulators - GW Pharmaceuticals (cannabigerol; CBG) – cannabinoid receptor modulators Research programme: cannabis extract therapeutics - Cannabis Science (CBIS compounds) – cannabinoid receptor modulators Research programme: central nervous system therapeutics - AbbVie/Rugen – undefined mechanism of action Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals – antioxidants, glutamate receptor modulators, SLC7A11 modulators Research programme: CNS disorders therapeutics - Sage Therapeutics (SAGE-105; SGE-202; SGE-301; SGE-516) – GABAA receptor modulators and ionotropic glutamate NMDA receptor modulators Research programme: G protein-coupled receptor modulating small molecules - Omeros Corporation – G protein-coupled receptor modulator and neuromedin U receptor modulator Research programme: GPCR modulators - Nxera Pharma – various actions Research programme: immunomodulating bacteria-based therapeutics - 4D Pharma – bacteria replacements Research programme: metabotropic glutamate receptor 5 antagonists - Roche/Seaside Therapeutics – metabotropic glutamate mGlu5 receptor antagonists Research programme: oxytocin intranasal - Pastorus Pharma – neurotransmitter modulators/oxytocin receptor agonists Research programme: therapeutic autoantibodies - Sengenics – undefined mechanism of action RG-7713 (RG7713) – vasopressin V1A receptor antagonist Tideglusib (AMO-02, NP-031112, NP-12; Nypta, Zentylor) – glycogen synthase kinase 3β (GSK-3β) inhibitor Vafidemstat (ORY-2001) – dual lysine specific demethylase 1 (LSD1) inhibitor and monoamine oxidase B (MAO-B) inhibitor Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist
Sources: en.wikipedia.org
=== Total synthesis === To summarize the total synthesis of Guanacastepene A, two independent synthetic routes are particularly relevant here. The first involves an attempt by Danishefsky and his colleagues to close the seven-membered B ring via an intramolecular Horner–Wadsworth–Emmons cyclization; however, this approach unexpectedly favored a kinetically preferred 5-exo cyclization instead. Ultimately, the seven-membered ring was formed via reductive cyclization of a vinyl iodide-ketone precursor, yielding the fused 5,7-ring hydroazulenone core. The quaternary stereocenter at C8 was then stereoselectively introduced via sequential Eschenmoser methylenation and conjugate cuprate addition. It was found that the order of alkylation determines the resulting stereochemistry. An intramolecular Knoevenagel cyclization was ultimately required to complete the guanacastane skeleton. This was achieved only after epoxidation of the corresponding olefin. This was followed by a Rubottom oxidation to introduce the characteristic acetoxy group at C13. The second, alternative, formal synthesis was developed by Hanna and his colleagues. Instead of forming the six- and seven-membered rings sequentially, they built the six- and seven-membered rings simultaneously in a single tandem ring-closing metathesis (RCM) reaction. Using a triene precursor, both quaternary stereocenters at C8 and C11 were established prior to the metathesis step. This was treated with the second-generation Grubbs catalyst in refluxing dichloromethane to directly yield the tricyclic skeleton.
In the 1960s, Ajinomoto began to diversify its production by securing alliances with international food companies, including the Kellogg Company in 1962, CPC International Inc. in 1963, and Best Foods Company Ltd. in 1964. Because of these partnerships, Ajinomoto began selling Kellogg's corn flakes and Knorr soup in Japan and created its own brand of mayonnaise. During this time period, Ajinomoto modified AJI-NO-MOTO's recipe by using amino acids from sugar cane instead of soybeans, which allowed the seasoning to be produced locally in the countries it was exported to, which reduced shipping costs for the company. Domestic production first began in Thailand in 1962, followed by the Philippines (previously established in 1958), Malaysia, Peru, Indonesia, and Brazil in subsequent years. By 1979, nearly half of all AJI-NO-MOTO was being produced outside of Japan. In the 1970s, Ajinomoto diversified further by launching a flavored seasoning called HON-DASHI in 1970 and producing frozen foods in 1972. In 1973 Ajinomoto and General Foods Inc. launched Ajinomoto General Foods Inc., a joint venture between the two companies that would sell instant coffee. In 1978, Ajinomoto launched a brand of Chinese seasonings under the brand name "Cook Do". In Asian and Latin American markets, Ajinomoto created new products for consumers, while the company primarily delivered its products to processed food manufacturers in Europe and the United States. During this era, the company also expanded into other product markets.
The British soldiers were well positioned on the hillside and inflicted casualties on the Boers charging on horseback over a large distance, beating them back. This was the end of the war in the Western Transvaal and the last major battle of the war.
Bone morphogenetic protein (rhBMP) should not be routinely used in any type of anterior cervical spine fusion, such as with anterior cervical discectomy and fusion. There are reports of this therapy causing swelling of soft tissue which in turn can cause life-threatening complications due to difficulty swallowing and pressure on the respiratory tract.
If an adsorbate molecule enters the precursor state at a location that is remote from any other previously adsorbed adsorbate molecules, the sticking probability is reflected by the size of the SD constant. These factors were included as part of a single constant termed a "sticking coefficient", kE, described below:
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.